[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microvascular-angina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microvascular-angina":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,73,114,134,178,209,238,272,294,318,345],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627491","self-expanding-coronary-sinus-reducer-for-treatment-of-symptomatic-coronary-microvascular-dysfunction-cmd-100627491",false,"NCT07449325","Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","SERRA-I US","Inclusion criteria\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure. Note: The LVEF must be reassessed after any intervening myocardial infarction. The most recent LVEF assessment is used as the qualifying test for subjects with multiple assessments\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II - IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy, as determined by Investigator and confirmed by the Central Screening Committee. Note: Optimal medical management is defined as at least 2 anti-anginal medications or maximally tolerated medical therapy if less than 2 anti-anginal medications.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators. RCA measurements are not permitted for this study.\n\n   Note: CFR should be measured in LAD or LCX if LAD is not feasible. RCA measurements are not permitted for this study\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n\n   Procedural Angiographic\u002FHemodynamic Inclusion Criteria:\n\n   The following will be assessed during the index procedure to confirm eligibility before an attempt at implantation. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators if not yet obtained in the prior 30 days (see inclusion criteria 4).\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion\n\nExclusion Criteria\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n\n   Note: subjects with an elevated troponin or CKMB without acute coronary syndrome may still be considered eligible.\n3. Extra-coronary contributory causes of angina- e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten, or known inability to tolerate contrast medium\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[27,28,29,30,31,32],"Angina Pectoris","Myocardial Ischemia","Heart Diseases","Cardiovascular Diseases","Vascular Diseases","Microvascular Angina","RECRUITING","2026-05-14",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":21},"2026-04",{"date":41,"type":21},"2027-12",{"name":43,"class":44},"VahatiCor, Inc.","INDUSTRY",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100521520","non-invasive-diagnosis-of-coronary-microvascular-disease-pilot-study-100521520","NCT06070662","Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study","Non-invasive Diagnosis of Coronary Microvascular Disease Using Novel CMR and CT Techniques: a Pilot Study","Inclusion Criteria:\n\n* Current participant of the 'CMR versus CT-FFR in CAD' study\n* Continue to meet the inclusion criteria for the main study:\n* Patients aged ≥18 years\n* Referred for invasive coronary angiography for investigation of chest pain\n* Willing and able to give informed consent\n* Willing and able (in the Investigators opinion) to comply with all study requirements.\n* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.\n* Able to understand written English\n* Able to perform exercise in the MRI scanner\n\nStudy arm:\n\n* No evidence of obstructive or non-obstructive CAD on research CTCA\n* Myocardial perfusion defect detected on adenosine stress CMR indicative of CMD\n\nControl arm:\n\n• Evidence of multivessel CAD on research CTCA\n\nExclusion Criteria:\n\n* Meet the exclusion criteria for the main study:\n* Recent acute coronary syndrome (\\\u003C 6 months)\n* Severe claustrophobia\n* Absolute contraindications to CMR - those with MR conditional or safe devices will be included\n* Second-\u002Fthird-degree atrioventricular block\n* Severe chronic obstructive pulmonary disease\n* Moderate-severe asthma\n* Estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2\n* Women who are pregnant, breast-feeding or of child-bearing potential (premenopausal women)\n* Contraindication to iodinated contrast\n* Participants who have participated in a research study involving an investigational product in the past 12 weeks\n* Patients unable to understand written English",{"count":54,"type":21},20,"OBSERVATIONAL","* 40% of patients presenting with stable chest pain (angina) have no significant blockage of the main heart arteries. Identifying why these patients have symptoms will mean better treatment options can be developed.\n* About 60% of these patients have evidence of coronary microvascular disease (CMD). In this condition there is a problem with the heart's microvessels (very small blood vessels that branch from the main heart arteries). Due to problems with these vessels there is a mismatch between the blood supply to the heart and its oxygen consumption, causing chest pain and this can also lead to major heart events.\n* At present, to diagnose this condition, specialised techniques during an invasive test, called a coronary angiogram, are required. As this is an invasive test, it can be lead to complications and cause discomfort.\n* Non-invasive ways of diagnosing CMD are required to improve the diagnosis and management of this condition.\n* This study aims to provide initial data on whether novel imaging techniques using CT and MRI scans, which are much less invasive, could identify CMD.\n* To do this, patients with suspected angina referred for angiography and who are already participants in the main research study 'CMR versus CT-FFR in CAD' study will be recruited.\n* These will be patients with suspected CMD and also those with blockage of the main heart arteries (triple vessel disease) to compare against.\n* Participants in this pilot study will have additional tests used to diagnose CMD during their invasive angiography procedure. Participants will then have an MRI scan involving novel techniques and exercise MRI, where individuals exercise use a cycle or stepping machine during the MRI scan. Further analysis will also be undertaken of CT images acquired as part of the main study.\n* These tests will be compared against invasive test results to see which show potential in being able to diagnose CMD.",[32],[59,60,61],"Coronary microvascular disease","Angina","Non-invasive testing","2026-04-29",{"date":64,"type":37},"2026-04-30",{"date":66,"type":37},"2023-11-01",{"date":68,"type":21},"2026-12",{"name":70,"class":71},"University of Leicester","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":95,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100414271","icormica---stratified-medicine-in-angina-100414271","NCT04674449","iCorMicA - Stratified Medicine in Angina","International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry","iCorMicA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. A clinical plan for invasive coronary angiography.\n3. Symptoms of angina (typical or atypical) according to the Rose- and\u002For Seattle Angina questionnaires.\n4. Able to comply with study procedures.\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).\n2. History of coronary artery bypass surgery.\n3. Presence of obstructive disease evident in a main coronary artery (diameter \\>2.5 mm), i.e. a coronary stenosis \\>50% and\u002For a fractional flow reserve (FFR) ≤0.80\\*.\n4. Logistical reason\\*. \\*These patients will enter a follow-up registry.",{"count":82,"type":21},1500,[24],"The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.",[32,86,87,88,89,90,91,92,93,94],"Angina, Stable","Ischemia With No Obstructive Coronary Arteries (INOCA)","Coronary Microvascular Dysfunction (CMD)","Ischaemic Heart Disease","Non-Obstructive Coronary Atherosclerosis","Coronary Artery Disease","Vasospastic Angina","Coronary; Ischemic","Angina Attacks",[96,97,98,99,100,101,102,103],"angina","microvascular angina","ischaemia with no obstructive coronary artery disease (INOCA)","stratified medicine","clinical trial","outcomes research","prognosis","health economics","2026-04-03",{"date":106,"type":37},"2026-04-09",{"date":108,"type":37},"2020-12-30",{"date":110,"type":21},"2030-12-31",{"name":112,"class":71},"NHS Greater Glasgow and Clyde",39,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":72},"100569323","the-value-of-measuring-retinal-vascular-density-by-optical-coherence-tomography-angiography-oct-a-in-patients-with-microvascular-angina-confirmed-by-myocardial-microcirculatory-resistance-index-mri-100569323","NCT06692751","The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).","EYE-NOCA","Inclusion Criteria:\n\n* Patients managed at Dijon University Hospital, having had an IMR measurement as part of INOCA during a coronary angiographic examination, consecutively includible, without angiographically or functionally significant coronary epicardial lesion (FFR \\\u003C 0.80) explaining the clinical picture (= INOCA)\n* Person having given oral consent\n* Adult\n\nExclusion Criteria:\n\n* Person not affiliated or not benefiting from a social security scheme\n* Person subject to a legal protection measure (curatorship, guardianship) or a safeguard of justice measure\n* Pregnant or breast-feeding women\n* An adult incapable or unable to give consent\n* Person with macular or retinal pathology, or severe bilateral myopia\n* Person with genetic or idiopathic cardiomyopathy (dilated, hypertrophic or restrictive cardiomyopathy)",{"count":122,"type":21},158,"Microvascular angina is thought to affect around 112 million patients worldwide. However, this figure is underestimated due to the difficulty of making the diagnosis. It is a pathology caused by an alteration in the microcirculation of the heart muscle, which is not detectable on a standard coronary angiogram.\n\nIn view of its prognostic, therapeutic and medico-economic value, scientific societies currently recommend invasive measurement of the microcirculatory resistance index (MRI) to diagnose microvascular angina, in the absence of significant lesions on coronary angiography.\n\nSeveral research teams, including our own, have shown that cardiovascular risk is associated with alterations in the vascularization of the small vessels (microcirculation) of the retina. Unlike the study of cardiac vessels, the study of retinal microcirculation using fundus photography (OCT-A) is simple, rapid, non-invasive and inexpensive. It appears to be an interesting alternative to the measurement of IMR for the diagnosis of microvascular angina.\n\nThis hypothesis has never yet been tested. The demonstration of an association between a decrease in retinal vascular density measured by OCT-A and an alteration in coronary microvascular function measured by IMR would pave the way for a completely non-invasive diagnosis of patients.\n\nThis is an observational, cohort, prospective, single-center pilot study comparing people who have received an IMR measurement as part of INOCA.\n\nIt is planned to include 158 participants. The overall follow-up period for each patient in the research is 12 months.\n\nIn routine care, IMR is measured during coronary angiography in patients presenting with ischemia on a non-invasive test and\u002For stress symptoms such as angina or dyspnea, for whom coronary angiography does not reveal any significant epicardial lesion.\n\nFollowing this examination, two groups will be formed: a group with an IMR\\\u003C25 and a group with an IMR≥25. Clinically, the study aims to determine the potential role of retinal OCT-A as a non-invasive examination for the diagnosis and\u002For follow-up of INOCA.",[32],"2026-02-12",{"date":127,"type":37},"2026-02-17",{"date":129,"type":37},"2024-11-13",{"date":131,"type":21},"2027-11",{"name":133,"class":71},"Centre Hospitalier Universitaire Dijon",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":55,"phases":4,"briefSummary":145,"conditions":146,"keywords":157,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":72},"100608041","polish-registry-of-cardioneuroablation-and-cardioneuromodulation-100608041","NCT07196397","POLish Registry of CArdioneuroablation and CArdioneuromodulation","POL-CA Registry: Multicenter Observational Study of Neuromodulatory Procedures in Cardiovascular Autonomic Dysfunction Syndromes","POL-CA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of at least one of the following conditions:\n\n  * Inappropriate sinus tachycardia (IST)\n  * Postural orthostatic tachycardia syndrome (POTS)\n  * Vasovagal syncope (VVS)\n  * Cardioinhibitory carotid sinus syndrome (CSS)\n  * Symptomatic sinus bradycardia or functional AV block\n  * Orthostatic hypotension (OH)\n* History of recurrent autonomic symptoms (e.g., syncope, bradycardia, palpitations, orthostatic intolerance)\n* Undergoing or previously underwent interventional treatment affecting cardiac autonomic innervation (e.g., cardioneuroablation, SN-sparing ablation, cardiac sympathetic denervation)\n* Provided written informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Structural heart disease requiring surgical intervention\n* Permanent pacemaker or ICD implanted prior to enrollment\n* Inability to complete follow-up assessments or questionnaires\n* Severe psychiatric comorbidities impairing participation\n* Participation in another interventional clinical trial",{"count":143,"type":21},1000,"3 Years","The multicentre observational study POL-CA involves a wide spectrum of patients with a history of syncopy. The study recruits patients with diagnosed vasovagal syndrome, cardioinhibitory carotid sinus syndrome, symptomatic sinus bradycardia or atrioventricular block, postural orthostatic tachycardia syndrome, orthostatic hypotension, and inappropriate sinus tachycardia syndrome. This is an observational, controlled study with retrospective, clinical data analysis of previously treated patients and the analysis of syncopal patients prospectively recruited into the study. The aim of the POL-CA registry is to create a platform for physicians to record treatment data for patients undergoing procedures that affect innervation or modify cardiovascular reflexes (cardioneuroablation, cardioneuromodulation) in order to provide a multicentre summary of population characteristics and treatment outcomes based on a standardized POL-CA questionnaire and methodology for various arrhythmias.",[147,148,149,150,151,152,92,32,153,154,155,156],"Vasovagal Syndrome VVS","Cardioinhibitory Carotid Sinus Syndrome CSS","Symptomatic Sinus Bradycardia SB or Atrioventricular Block AV","Postural Orthostatic Tachycardia Syndrome POTS","Orthostatic Hypotension","Inappropriate Sinus Tachycardia Syndrome IST","Ventricular Arrythmia","Raynaud Phenomena","Autonomic Dysfunction","Autonomic Diseases",[158,159,160,161,162,163,164,165,166,167],"cardioneuroablation","cardiac sympathetic denervation","sinoatrial node sparing hybrid ablation","catheter ablation","neural stimulation","cardioneuromodulation","percutaneus stellate ganglion blockage","cardiac rehabilitation","cardiovascular autonomic tests","syncope","2025-09-21",{"date":170,"type":37},"2025-09-29",{"date":172,"type":37},"2024-11-21",{"date":174,"type":21},"2031-12-31",{"name":176,"class":177},"SABAMED Medical Center Ltd.","NETWORK",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":187,"studyType":55,"phases":4,"briefSummary":188,"conditions":189,"keywords":195,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":72},"100600886","comprehensive-coronary-physiology-in-patients-with-angina-with-nonobstructive-coronary-arteries---czech-republic-100600886","NCT07103317","Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","Comprehensive COROnary PHYSiology Assessment in Patients With Angina With Nonobstructive Coronary Arteries - CZECH Republic (CoroPhys-CZECH)","CoroPhys-CZ","Inclusion Criteria:\n\n* Adults of both sexes older than 18 years\n* Angina symptoms or angina equivalent\n* Referred to cath lab for evaluation of CAD\n* Invasive physiology testing performed (microcirculation testing +\u002F- vasospasm testing)\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Pregnant of nursing\n* No coronary physiology measurements were performed",{"count":143,"type":21},"100 Years","Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of microcirculation and vasospastic disorders in causing angina. The microvascular bed is composed of vessels smaller than 400 microns in diameter. Their network is significantly larger than that of the epicardial vessels and serves essential functions, including regulating myocardial blood flow and cellular metabolism.\n\nAngina pectoris, a most frequent symptom of CAD or myocardial ischemia, was assumed to be caused by significant stenosis of the epicardial coronary artery. However, it was found that in over 50% of cases, there was no obstructive CAD, which is described as angina with no obstructive coronary arteries (ANOCA) or ischemia with no obstructive coronary arteries (INOCA), according to the clinical setting.",[190,191,192,193,32,92,194],"ANOCA","ANOCA - Angina With Non-obstructive Coronary Arteries","MINOCA","Microvascular Dysfunction","Acetylcholine",[190,196,192,197,32,92,198,199],"INOCA","Coronary Microvascular Dysfunction","Acetylcholine Testing","Coronary Termodilution","2025-08-01",{"date":202,"type":37},"2025-08-05",{"date":204,"type":37},"2023-04-20",{"date":206,"type":21},"2030-01-01",{"name":208,"class":71},"University Hospital, Motol",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":45},"100568489","microvascular-coronary-rehabilitation-for-improving-treatment---feasibility-study-100568489","NCT06681896","Microvascular Coronary Rehabilitation For Improving Treatment - Feasibility Study","MICROFIT","Inclusion Criteria:\n\n* Age ≥18\n* Angina or angina equivalent symptoms\n* Unobstructed coronary arteries at the time of coronary angiogram. This will be defined as plaque causing \\\u003C40% epicardial vessel stenosis or 40-90% with a fractional flow reserve (FFR) ≥0.8\n* Evidence of microvascular dysfunction on ICA (CFR \\\u003C2.5 and\u002For AchFR \\\u003C1.5)\n\nExclusion Criteria:\n\n* New York Heart Association class III\u002FIV heart failure\n* Severe left ventricular impairment (ejection fraction≤35%)\n* Severe heart valve disease\n* Significant cardiomyopathy (as assessed by a cardiologist)\n* Severe hypertension (defined as blood pressure \\>180\u002F120mmHg (despite three anti-hypertensive agents)\n* Uncontrolled arrhythmia\n* A history of aortic dissection, recent (\\\u003C6 months) acute pulmonary embolus, deep vein thrombosis, stroke or transient ischaemic attack, severe autonomic or peripheral neuropathy, acute systemic illness or fever, severe acute or chronic renal failure, severe pulmonary fibrosis or interstitial lung disease (in line with other trials investigating HIIT exercise)\n* Pregnancy or breastfeeding (at any point during the study. Patients becoming pregnant during the study will be asked to withdraw due to additional radiation exposure and risks from HIIT)\n* Physical inability to participate in exercise\n* Significant claustrophobia or metallic implants which would limit MRI imaging\n* Intolerance to regadenoson testing (high degree atrioventricular block, severe asthma or airways disease)\n* Current participation in another intervention-based trial\n* Inability to fully understand the verbal and written descriptions of the study and instructions provided during the study duration.",{"count":217,"type":21},40,[24],"The goal of this clinical trial is to assess the feasibility of undertaking a randomized controlled trial assessing the impact of a personalised, intense cardiac rehabilitation programme involving high intensity interval exercise (HIIT) and dietary advice (termed MICROFIT) on symptom burden in patients with microvascular coronary dysfunction.\n\nThe main questions it aims to answer are:\n\n1. Feasibility of undertaking randomised controlled trial of MICROFIT in patients with coronary microvascular dysfunction (recruitment rates, retention and adherence, acceptability of MICROFIT and participants' and practitioners' experiences of trial participation)\n2. Preliminary data on the effect that MICROFIT has on angina symptoms in patients with microvascular coronary dysfunction, as measured by Seattle Angina Questionnaire\n3. Preliminary data on the fidelity and clinical efficacy of MICROFIT\n\nParticipants will be randomized to either MICROFIT + Usual Care, or Usual Care group.\n\nParticipants in both arms of the trial will:\n\n* Undergo a series of investigations, including cardiopulmonary exercise test (CPET), dual xray absorptiometry (DEXA), echocardiogram, cardiac MRI scan, blood tests, at the start of the trial and again after 6 months\n* Measure their living activity by using an activity tracker (GeneActiv) as well as a photographic diet diary for a week at the start of the trial and again after 6 months\n* Complete a series of questionnaires to assess angina symptom burden, mental health and quality of life, at the start of the trial and again after 6 months.\n\nParticipants in the intervention arm of the study will:\n\n1. Undergo MICROFIT intervention. MICROFIT includes a combination of exercise and diet management sessions over 24 weeks. It involves:\n\n   * 1:1 high-intensity interval training ('HIIT') sessions with a personal trainer and guidance on exercise sessions to be performed at home\n   * 1:1 sessions with a dietician to support them with improvements in diet.\n2. Visit clinic on two additional occassions during the trial to discuss their progress with a cardiologist\n3. Undergo an interview at the end of the study to discuss their experiences of participation in the study\n4. Receive a debrief on their investigation results and progress made at the end of their study\n\nParticipants in the Usual Care arm of the study will:\n\n1. Receive standard Usual Care advice regarding lifestyle changes and targeted medical therapy offered to patients with coronary microvascular dysfunction.\n2. Receive a debrief on their investigation results and progress made at the end of their study\n3. Undergo a 'taster' session with the personal trainer to discover what the intervention involves.",[221,32,88],"Microvascular Coronary Dysfunction",[223,224,225,226,227,228,97],"coronary microvascular dysfunction","HIIT","high intensity interval exercise training","exercise training","dietary rehabilitation","lifestyle advice","2025-06-17",{"date":231,"type":37},"2025-06-18",{"date":233,"type":37},"2024-11-12",{"date":235,"type":21},"2027-01-01",{"name":237,"class":71},"Royal United Hospitals Bath NHS Foundation Trust",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":254,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":72},"100477065","coronary-sinus-reducer-implantation-in-patients-with-ischaemia-and-non-obstructed-coronary-arteries-and-coronary-microvascular-dysfunction-100477065","NCT05492110","Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.","REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study","REMEDY-PILOT","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.\n3. Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.\n4. Unobstructed coronary arteries with ≤50% epicardial stenoses demonstrated on coronary angiography.\n5. Stress-induced hypoperfusion on CMR (Global MPR ≤ 2.2).\n6. Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.\n7. Understands the nature of the trial procedures and provides written informed consent.\n\nExclusion Criteria:\n\n1. Epicardial CAD in a main coronary artery (stenoses \\>50%, RFR≤0.92 or FFR≤0.80), coronary artery bypass grafting, or myocardial infarction (MI).\n2. Previous PCI within 6 months\n3. PCI with stent insertion for acute MI or chronic total occlusion (CTO)\n4. Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)\n5. Coronary sinus diameter at site of implant \\\u003C9.5mm or \\>13mm\n6. Mean right atrial pressure \\\u003C15mmHg at time of implantation\n7. Any structural heart disease including left ventricular hypertrophy; cardiomyopathy; severe valvular heart disease; previous valve replacement; myocardial bridge on angiography; LVEF\\\u003C45% by CMR.\n8. Clinically or angiographically diagnosed coronary vasospasm\n9. Previous hospitalisation for decompensated heart failure\n10. Pacemaker or defibrillator electrode in the right atrium, right ventricle or coronary sinus\n11. Documented arrhythmia requiring planned implantation of a permanent pacemaker or defibrillator\n12. Chronic kidney disease (creatinine \\>200 micromol\u002FL; established on renal replacement therapy; functioning renal transplant)\n13. Haemoglobin \\\u003C80g\u002FL\n14. Contraindications to receiving dual antiplatelet therapy\n15. Severe chronic obstructive pulmonary disease (FEV1 \\\u003C55% predicted)\n16. Moribund patients with life expectancy \\\u003C 1year\n17. Known allergy to nickel or steel\n18. Current enrolment in another investigational device or drug trial\n19. Contraindications to CMR or receiving intravenous adenosine\n20. Pregnancy",{"count":247,"type":21},54,[24],"To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.",[251,32,252,253,27],"Refractory Angina","Microvascular Coronary Artery Disease","Coronary Disease",[255,256,257,258,259,260,261,262],"Angina pectoris","Refractory angina","Microvascular angina","Coronary microvascular dysfunction","Coronary sinus reducer","Chest pain","Coronary disease","Myocardial ischaemia","2025-03-31",{"date":265,"type":37},"2025-04-03",{"date":267,"type":37},"2023-04-17",{"date":269,"type":21},"2026-03-06",{"name":271,"class":71},"Imperial College London",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":72},"100521973","sex-difference-of-coronary-microvascular-dysfunction-in-patients-with-non-obstructive-coronary-artery-disease-100521973","NCT06076551","Sex Difference of Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease","Sex Difference of Coronary Microvascular Dysfunction Evaluated by Coronary Flow Reserve in Patients With Non-obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* Typical\u002Fatypical chest pain or ischemic symptoms including dyspnea\n* No significant coronary artery stenosis (\\\u003C50% stenosis) in coronary angiography or computed tomography\n\nExclusion Criteria:\n\n* ≥ Moderate valvular heart disease\n* Congenital heart disease\n* Chronic renal failure (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis\n* Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension\n* Receiving anticancer drugs\n* Vasculitis associated with autoimmune diseases\n* Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients","20 Years","80 Years",{"count":282,"type":21},300,"Sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed in patients with non-obstructive coronary artery disease",[32],"2025-03-24",{"date":287,"type":37},"2025-03-26",{"date":289,"type":37},"2018-02-01",{"date":291,"type":21},"2025-12-31",{"name":293,"class":71},"Korea University Anam Hospital",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":316,"locationsCount":72},"100548733","phase-2-efficacy-of-targeted-medical-therapy-in-angina-and-nonobstructive-coronary-arteries-100548733","NCT06424834","Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries","A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study","MVP-ANOCA","Inclusion Criteria:\n\n* All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.\n\nSpecific inclusion criteria for randomization:\n\n* Absence of significant epicardial coronary artery disease on angiography\n* Fractional flow reserve \\> 0.80\n\nAnd ≥ 1 of the following:\n\n* Epicardial coronary spasm on acetylcholine testing\n* Microvascular spasm on acetylcholine testing\n* Coronary flow reserve \\\u003C 2.5\n* Index of microcirculatory resistance ≥ 25\n* Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76\n\nExclusion Criteria:\n\n* Acute coronary syndrome less than one week prior to enrolment\n* Cardiomyopathy\n* Contraindications to beta-blockers or calcium channel blockers\n* Baseline systolic blood pressure \\\u003C 95 mmHg\n* Baseline heart rate \\\u003C 55 bpm",{"count":303,"type":21},150,[305,306],"PHASE2","PHASE3","The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.\n\nParticipants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.",[27,32,92,309],"Myocardial Bridge of Coronary Artery","2024-11-26",{"date":312,"type":37},"2024-11-27",{"date":314,"type":37},"2024-10-10",{"date":68,"type":21},{"name":317,"class":71},"Stanford University",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":329,"studyType":55,"phases":4,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":72},"100534809","relationship-between-coronary-microvascular-dysfunction-and-improvement-of-left-ventricular-systolic-function-in-patients-with-heart-failure-with-reduced-ejection-fraction-caused-by-non-ischemic-etiology-100534809","NCT06243653","Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology","The Role of Coronary Microvascular Dysfunction in Improving Left Ventricular Systolic Function Using Registry for Evaluation of Factors associatEd With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology (REFERENCE).","HFrEF-CMD","Inclusion Criteria:\n\n* a) Subject must be at least 19 years of age. b) Subject with symptoms or signs of HF (NYHA ≥2 dyspnea) and reduced ejection fraction (LVEF ≤ 40%) c) Subject who clinically need coronary angiography d) Subject who can voluntarily sign informed consent form\n\nExclusion Criteria:\n\n* a) Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis ≥90% or 50-90% with fractional flow reserve \\[FFR\\] ≤0.80) b) Subject scheduled for cardiac replacement therapy (heart transplantation or left ventricular assisted device \\[LVAD\\] implantation) c) HF due to restrictive cardiomyopathy, active myocarditis, or constrictive pericarditis d) Significant valvular heart disease requiring surgery e) Subject who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year","19 Years",{"count":328,"type":21},200,"1 Year","This study aims to evaluate the incidence of coronary microvascular dysfunction (CMD) and its prognostic implication for the improvement of left ventricular function in patients who have been diagnosed with heart failure with reduced ejection fraction (HFrEF) caused by non-ischemic etiology.",[332,32,333],"Heart Failure","Non-ischemic Cardiomyopathy",[223,335],"non-ischemic cardiomyopathy","2024-02-05",{"date":338,"type":37},"2024-02-06",{"date":340,"type":37},"2023-08-09",{"date":342,"type":21},"2027-12-31",{"name":344,"class":71},"Samsung Medical Center",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":72},"100523216","phase-4-microvascular-angina-intervention-with-compound-danshen-dripping-pill-maids-100523216","NCT06092736","Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS)","MAIDS","Inclusion criteria:\n\n1. with typical symptoms of exertional angina;\n2. coronary CTA or angiography with normal coronary artery or \\\u003C50% stenosis, or \\\u003C50% residual coronary stenosis after revascularization;\n3. resting electrocardiogram or During exercise stress, it was found that the ST segment had an ischemic downward shift (the horizontal or downward slope after the J-point shift \\> 0.1 mv, lasting 0.08 s);\n4. Transthoracic ultrasound examination of blood in the anterior descending coronary artery before and after intravenous injection of adenosine Flow reserve check CFR\\\u003C2.5;\n5. The patient himself agrees to participate in this study.\n\nExclusion criteria\n\n1. Less than 30 years old or more than 75 years old;\n2. Have a history of carotid endarterectomy or stent implantation, and have a history of stroke;\n3. Myocarditis, pericardial disease, valvular disease, cardiomyopathy;\n4. Difficult to control diabetes mellitus (fasting blood glucose\\>7.0 mmol\u002FL);\n5. Uncontrolled hypertension (SBP\\>150 mmHg and\u002For DBP\\>90 mmHg);\n6. Familial hypercholesterolemia;\n7. Multiple Takayasu arteritis;\n8. Those who are pregnant or lactating, or have fertility intention within one year, or have not taken effective contraceptive measures during the childbearing period;\n9. Abnormal liver function (the level of serum GPT is 3.0 times higher than the upper limit of normal value) or abnormal renal function (the level of serum creatinine is more than 2 mg\u002Fdl);\n10. Other respiratory, digestive, blood, infection, immunity, endocrine, neuropsychiatric, tumor diseases with clinical significance that may cause serious danger to patients;\n11. Taking traditional Chinese medicine preparations of K channel opener, promoting blood circulation and removing blood stasis to improve microcirculation;\n12. Allergies to intra arterial injection of contrast agents, blood and blood products;\n13. Patients who are participating in other clinical studies.","30 Years","75 Years",{"count":355,"type":21},100,[357],"PHASE4","Coronary microvascular disease (MVD) refers to exertional angina or myocardial ischemia caused by abnormal structure and\u002For function of precoronary arterioles and arterioles under the action of various pathogenic factors. The symptoms of patients with coronary microvascular disease are mainly exertion-related chest pain episodes.\n\nThe basic and clinical researches of the traditional Chinese medicine compound Danshen dropping pills have found that it can improve vascular endothelial function and relieve angina pectoris, and it is widely used in clinical practice.\n\nThis is a randomized, double-blind, placebo-controlled, multicenter clinical study of Compound Danshen Dropping Pills and blank control in patients with microvascular angina pectoris.\n\nThe experimental drug and control drug of this clinical trial were selected according to the ratio of 1:1 patients were enrolled in the pre-experiment.\n\nAfter the selected patients signed the informed consent, they were divided into a compound Danshen dripping pill treatment group and a placebo group according to a random, double-blind, placebo-controlled method. Dosage of Compound Danshen Dropping Pills or placebo: 20 capsules each time, 3 times a day, for a total of 6 months. Follow-up was performed every 2 months for a total of 6 months.\n\nPrimary study endpoints is the difference of the left anterior descending coronary flow reserve (CFR) measured by ultrasound between the two groups compared with the baseline.\n\nSecondary study endpoint include the Number of angina attacks per week, the time of angina pectoris and the time of ischemic ST segment depression in exercise test.",[32],[361,32,362,363],"Coronary Blood Flow Reserve","Compound Danshen Dripping Pill","echocardiography","2023-10-15",{"date":366,"type":37},"2023-10-23",{"date":368,"type":37},"2018-12-18",{"date":370,"type":21},"2028-06-30",{"name":372,"class":71},"Qilu Hospital of Shandong University"]